The crucial role of LncRNA MIR210HG involved in the regulation of human cancer and other disease

Lü, Juan; Zhu, Dan; Zhang, Xiaoqian; Wang, Jie; Cao, Hongcui; Li, Lanjuan

doi:10.1007/s12094-022-02943-3

Cited by 3 publications

(3 citation statements)

References 181 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell culture studies and clinical data show that there is an association between drug resistance and the abnormal expression of MIR210HG in certain cancers, including GBM, pancreatic cancer, non-small cell lung cancer, ERPR/Her2-type breast carcinoma, and colorectal cancer. These data make MIR210HG a novel therapeutic target that could improve tumour sensitivity to radiotherapy and chemotherapy and inhibit neoplastic process [45,303,305]. Elevated levels of MIR210HG expression have been found in other cancers, with its higher levels reported in hepatocellular carcinoma tissue, which correlates with the clinical stage of the disease and tumour characteristics, including size, vascular invasion, and histological differentiation.…”

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 91%

“…The abnormal expression of MIR210HG was found in pancreatic tumour tissue and its level is also associated with the survival time of patients [307]. Expressional changes are also associated with the clinical presentation of patients with osteosarcoma, as well as breast cancer, colorectal cancer, gastric cancer, cervical cancer, and ovarian cancer [303]. Interestingly, this lncRNA is overexpressed in the sperm of infertile men with varicocele and negatively correlates not only with the quantity of sperm but also with the motility of the sperm [308].…”

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 95%

“…MIR210HG (MIRNA210 host gene) is an oncogenic GBM lncRNA [45] and is deregulated in other cancers (liver, lung, pancreatic, breast, gastric, cervical, ovarian, and colorectal) and non-cancerous diseases such as preeclampsia, acute renal injury, and others [303]. MIR210HG is involved in cell proliferation, migration and invasion, energy metabolism, autophagy, hypoxia, radiosensitivity, and chemoresistance.…”

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

See 2 more Smart Citations

lncRNA Biomarkers of Glioblastoma Multiforme

Pokorná,

Černá,

Boussios

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are RNA molecules of 200 nucleotides or more in length that are not translated into proteins. Their expression is tissue-specific, with the vast majority involved in the regulation of cellular processes and functions. Many human diseases, including cancer, have been shown to be associated with deregulated lncRNAs, rendering them potential therapeutic targets and biomarkers for differential diagnosis. The expression of lncRNAs in the nervous system varies in different cell types, implicated in mechanisms of neurons and glia, with effects on the development and functioning of the brain. Reports have also shown a link between changes in lncRNA molecules and the etiopathogenesis of brain neoplasia, including glioblastoma multiforme (GBM). GBM is an aggressive variant of brain cancer with an unfavourable prognosis and a median survival of 14–16 months. It is considered a brain-specific disease with the highly invasive malignant cells spreading throughout the neural tissue, impeding the complete resection, and leading to post-surgery recurrences, which are the prime cause of mortality. The early diagnosis of GBM could improve the treatment and extend survival, with the lncRNA profiling of biological fluids promising the detection of neoplastic changes at their initial stages and more effective therapeutic interventions. This review presents a systematic overview of GBM-associated deregulation of lncRNAs with a focus on lncRNA fingerprints in patients’ blood.

show abstract

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 91%

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 95%

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

See 1 more Smart Citation

lncRNA Biomarkers of Glioblastoma Multiforme

Pokorná,

Černá,

Boussios

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

Pan-cancer analyses identify MIR210HG overexpression, epigenetic regulation and oncogenic role in human tumors and its interaction with the tumor microenvironment

Yadav,

Kulshreshtha

2024

Life Sciences

View full text Add to dashboard Cite

Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma

Wang,

Shu

2024

CMC

View full text Add to dashboard Cite

BACKGROUND: RNA methylation modification is not only intimately interrelated with cancer development and progression but also actively influences immune cell infiltration in the tumor microenvironment (TME). RNA methylation modification genes influence the therapeutic progression of lung adenocarcinoma (LUAD), and mining RNA methylation modification prognosis-related markers in LUAD is crucial for its precise prognosis. METHODS: RNA-Seq data and Gene sets were collected from online databases or published literature. Genomic variation analysis was conducted by the Maftools package. RNA methylation-immune-related lncRNAs were obtained by Pearson correlation analysis. Then, Consistent clustering analysis was performed to obtain RNA methylation modification-immune molecular subtypes (RMM-I Molecular subtypes) in LUAD based on selected lncRNAs. COX and random survival forest analysis were carried out to construct the RMM-I Score. The receiver operating characteristic (ROC) curve and Kaplan Meier survival analysis were used to assess survival differences. Tumor immune microenvironment was assessed through related gene signatures and CIBERSORT algorithm. In addition, drug sensitivity analysis was executed by the pRRophetic package. RESULTS: Four RNA methylation modified-immune molecular subtypes (RMM-I1, RMM-I2, RMM-I3, RMM-I4) were presented in LUAD. Patients in RMM-I4 exhibited excellent survival advantages and immune activity. HAVCR2, CD274, and CTLA-4 expression were activated in RMM-I4, which might be heat tumors and a potential beneficial group for immunotherapy. OGFRP1, LINC01116, DLGAP1-AS2, CRNDE, LINC01137, MIR210HG, and CYP1B1-AS1 comprised the RMM-I Score. The RMM-I Score exhibited excellent accuracy in the prognostic assessment of LUAD, as patients with a low RMM-I Score exhibited remarkable survival advantage. Patients with a low RMM-I score might be more sensitive to treatment with Docetaxel, Vinorelbine, Paclitaxel, Cisplatin, and immunotherapy. CONCLUSION: The RMM-I molecular subtype constituted the novel molecular characteristic subtype of LUAD, which complemented the existing pathological typing. More refined and accurate molecular subtypes provide help to reveal the mechanism of LUAD development. In addition, the RMM-I score offers a reliable tool for accurate prognosis of LUAD.

show abstract

The crucial role of LncRNA MIR210HG involved in the regulation of human cancer and other disease

Cited by 3 publications

References 181 publications

lncRNA Biomarkers of Glioblastoma Multiforme

lncRNA Biomarkers of Glioblastoma Multiforme

Pan-cancer analyses identify MIR210HG overexpression, epigenetic regulation and oncogenic role in human tumors and its interaction with the tumor microenvironment

Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma

Contact Info

Product

Resources

About